Skip to main content
Erschienen in: Medical Oncology 1/2016

01.01.2016 | Original Paper

hcrcn81 promotes cell proliferation through Wnt signaling pathway in colorectal cancer

verfasst von: Yao Chen, Tingting Jiang, Lihong Shi, Kunyan He

Erschienen in: Medical Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The objective of the study was to investigate the role of hcrcn81 gene in Wnt/β-catenin signaling pathway related to human colorectal cancer. A total of 30 pairs of human colorectal cancer tissues with control normal tissues were analyzed by qRT-PCR. The proliferation, apoptosis, cell cycle, cell colony and metastasis of LS174T−hcrcn81, HCT116−hcrcn81, LoVo+hcrcn81 and SMMC-7721+hcrcn81 cells were tested, of which hcrcn81 was knockdown in LS174T, HCT116 cells and hcrcn81 was overexpressed in LoVo, SMMC-7721 cells. Besides, the mRNA and protein levels of hcrcn81, β-catenin, c-Myc, cyclinD1, GSK-3β and survivin in colon cancer cell lines were evaluated by qRT-PCR and western blot. The mRNA levels of β-catenin and Survivin were up-regulated in 76.7 % (23/30) and 63.3 % (19/30) of the tumor samples, respectively. hcrcn81 and GSK-3β mRNA expression levels were down-regulated in 20/30 (66.7 %) and 21/30 (70.0 %) of the tumor samples as compared to the adjacent normal tissues, respectively. Furthermore, in LoVo+hcrcn81 and SMMC-7721+hcrcn81 cells, the mRNA and protein levels of β-catenin, c-Myc, cyclinD1 and Survivin were up-regulated, whereas those of GSK-3 were down-regulated. In LS174T−hcrcn81 and HCT116−hcrcn81 cells, the mRNA levels of β-catenin, c-Myc, cyclinD1 and Survivin were down-regulated, whereas GSK-3βmRNA was up-regulated. Cell proliferation in LoVo+hcrcn81 and SMMC-7721+hcrcn81 groups was significantly enhanced (P < 0.05). Proliferation index in both LoVo+hcrcn81 and SMMC-7721+hcrcn81 groups was significantly higher than that in the control groups (P < 0.05). The number of colony in LoVo+hcrcn81 and SMMC-7721+hcrcn81 cells were significantly higher than that in the control groups (P < 0.05). In addition, the percentage of apoptotic cells in LoVo+hcrcn81 and SMMC-7721+hcrcn81 groups were significantly lower than that in the control groups (P < 0.01, P < 0.01). Finally, the number of migrating cells was significantly higher in LoVo+hcrcn81 and SMMC-7721+hcrcn81 groups than that in the control group (P < 0.05). hcrcn81 might promote carcinogenesis and progression through regulation of the Wnt/β-catenin signaling pathway and plays an important role in the carcinogenesis of colorectal cancer.
Literatur
1.
Zurück zum Zitat Bosetti C, Levi F, Rosato V, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2011;129:180–91.CrossRefPubMed Bosetti C, Levi F, Rosato V, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2011;129:180–91.CrossRefPubMed
2.
Zurück zum Zitat Xue HH, Zhao DM. Regulation of mature T cell responses by Wnt signaling pathway. Ann N Y Acad Sci. 2012;1247(1):16–33.CrossRefPubMed Xue HH, Zhao DM. Regulation of mature T cell responses by Wnt signaling pathway. Ann N Y Acad Sci. 2012;1247(1):16–33.CrossRefPubMed
3.
Zurück zum Zitat Wu S-C, Chen WT-L, Muo C-H, Ke T-W, Fang C-W, Sung F-C. Association between appendectomy and subsequent colorectal cancer development: an Asian population study. PLoS One. 2014;10(2):1–13. Wu S-C, Chen WT-L, Muo C-H, Ke T-W, Fang C-W, Sung F-C. Association between appendectomy and subsequent colorectal cancer development: an Asian population study. PLoS One. 2014;10(2):1–13.
4.
Zurück zum Zitat Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med. 2012;10(1):128.PubMedCentralCrossRefPubMed Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med. 2012;10(1):128.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012;27(9):1423–31.CrossRefPubMed Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012;27(9):1423–31.CrossRefPubMed
6.
Zurück zum Zitat Weber GF, Rosenberg R, Murphy JE, Meyer zum Buschenfelde C, Friess H. Multimodal treatment strategies for locally advanced rectal cancer. Expert Rev Anticancer Ther. 2012;12(4):481–94.CrossRefPubMed Weber GF, Rosenberg R, Murphy JE, Meyer zum Buschenfelde C, Friess H. Multimodal treatment strategies for locally advanced rectal cancer. Expert Rev Anticancer Ther. 2012;12(4):481–94.CrossRefPubMed
7.
Zurück zum Zitat Dewdney A, Cunningham D. Toward the non-surgical management of locally advanced rectal cancer. Curr Oncol Rep. 2012;14(3):267–76.CrossRefPubMed Dewdney A, Cunningham D. Toward the non-surgical management of locally advanced rectal cancer. Curr Oncol Rep. 2012;14(3):267–76.CrossRefPubMed
8.
Zurück zum Zitat Jiang Q, Zhang C, Chen Y. NM_001013649. 3 gene is down-regulated in human colorectal adenocarcinoma. Mol Med Rep. 2011;4(6):1279–81.PubMed Jiang Q, Zhang C, Chen Y. NM_001013649. 3 gene is down-regulated in human colorectal adenocarcinoma. Mol Med Rep. 2011;4(6):1279–81.PubMed
9.
Zurück zum Zitat Wen X, Dong L, Zhu J, Chen Y. hcrcn81 is upregulated by rapamycin treatment in human colorectal adenocarcinoma. Mol Med Rep. 2013;7:1257–60.PubMed Wen X, Dong L, Zhu J, Chen Y. hcrcn81 is upregulated by rapamycin treatment in human colorectal adenocarcinoma. Mol Med Rep. 2013;7:1257–60.PubMed
10.
Zurück zum Zitat Chen Y, Zhang YZ, Zhou ZG, et al. Identification of differentially expressed genes in human colorectal adenocarcinoma. World J Gastroenterol. 2006;12:1025–32.PubMedCentralPubMed Chen Y, Zhang YZ, Zhou ZG, et al. Identification of differentially expressed genes in human colorectal adenocarcinoma. World J Gastroenterol. 2006;12:1025–32.PubMedCentralPubMed
11.
Zurück zum Zitat Wang KC, Chen Y. Analysis of the novel protein in human colorectal adenocarcinoma. Mol Med Rep. 2013;8:529–34.PubMed Wang KC, Chen Y. Analysis of the novel protein in human colorectal adenocarcinoma. Mol Med Rep. 2013;8:529–34.PubMed
12.
Zurück zum Zitat Jiang T, Wen X, Chen Y. Effect of silencing c2orf68 gene on the proliferation of colorectal adenocarcinoma cells. China Biotechnol. 2014;34(2):7–13. Jiang T, Wen X, Chen Y. Effect of silencing c2orf68 gene on the proliferation of colorectal adenocarcinoma cells. China Biotechnol. 2014;34(2):7–13.
13.
Zurück zum Zitat Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009;10(7):468–77.CrossRefPubMed Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009;10(7):468–77.CrossRefPubMed
15.
Zurück zum Zitat Song JL, Nigam P, Tektas SS, et al. microRNA regulation of Wnt signaling pathways in development and disease. Cell Signal. 2015;S0898–6568(15):115–7. Song JL, Nigam P, Tektas SS, et al. microRNA regulation of Wnt signaling pathways in development and disease. Cell Signal. 2015;S0898–6568(15):115–7.
16.
Zurück zum Zitat Marcel V, Catez F, Diaz JJ. p53, a translational regulator: contribution to its tumour-suppressor activity. Oncogene. 2015;34:5513–5523. Marcel V, Catez F, Diaz JJ. p53, a translational regulator: contribution to its tumour-suppressor activity. Oncogene. 2015;34:5513–5523.
17.
Zurück zum Zitat Altieri DC. Survivin—the inconvenient IAP. Semin Cell Biol. 2015;S1084–9521(15):3–8. Altieri DC. Survivin—the inconvenient IAP. Semin Cell Biol. 2015;S1084–9521(15):3–8.
18.
Zurück zum Zitat Koehler BC, Jäger D, Schulze-Bergkamen H. Targeting cell death signaling in colorectal cancer: current strategies and future perspectives. World J Gastroenterol. 2014;20(8):1923–34.PubMedCentralCrossRefPubMed Koehler BC, Jäger D, Schulze-Bergkamen H. Targeting cell death signaling in colorectal cancer: current strategies and future perspectives. World J Gastroenterol. 2014;20(8):1923–34.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Koldobskiy MA, Chakraborty A, Werner JK Jr, et al. p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. Proc Natl Acad Sci USA. 2010;107:20947–51.PubMedCentralCrossRefPubMed Koldobskiy MA, Chakraborty A, Werner JK Jr, et al. p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. Proc Natl Acad Sci USA. 2010;107:20947–51.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Golpich M, Amini E, Hemmati F. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson’s disease. Pharmacol Res. 2015;18(15):43–9. Golpich M, Amini E, Hemmati F. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson’s disease. Pharmacol Res. 2015;18(15):43–9.
21.
Zurück zum Zitat Tsai KH, Hsien HH, Chen LM, et al. Rhubarb inhibits hepatocellular carcinoma cell metastasis via GSK-3β activation to enhance protein degradation and attenuate nuclear translocation of β-catenin. Food Chem. 2013;138(1):278–85.CrossRefPubMed Tsai KH, Hsien HH, Chen LM, et al. Rhubarb inhibits hepatocellular carcinoma cell metastasis via GSK-3β activation to enhance protein degradation and attenuate nuclear translocation of β-catenin. Food Chem. 2013;138(1):278–85.CrossRefPubMed
22.
Zurück zum Zitat Amado NG, Predes D, Moreno MM, et al. Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies. Int J Mol Sci. 2014;15(7):12094–106.PubMedCentralCrossRefPubMed Amado NG, Predes D, Moreno MM, et al. Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies. Int J Mol Sci. 2014;15(7):12094–106.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Sebio A, Kahn M, Lenz HJ. The potential of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther Targets. 2014;18(6):611–5.CrossRefPubMed Sebio A, Kahn M, Lenz HJ. The potential of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther Targets. 2014;18(6):611–5.CrossRefPubMed
Metadaten
Titel
hcrcn81 promotes cell proliferation through Wnt signaling pathway in colorectal cancer
verfasst von
Yao Chen
Tingting Jiang
Lihong Shi
Kunyan He
Publikationsdatum
01.01.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0713-9

Weitere Artikel der Ausgabe 1/2016

Medical Oncology 1/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.